Jessie Barnum, M.D.

  • Assistant Professor of Pediatrics

Major Lectureships and Seminars

  • “Infectious complications after BMT,” APHON course, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., September 2016, February 2017 and June 2017
  • “Renal complications after BMT”,” APHON course, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., September 2016, February 2017 and June 2017
  • “Critical Illness after BMT: Respiratory complications,” PICU Fellow Didactic Session, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., November 2016
  • “Tolerance Strategies,” BMT and liver transplant focus group on immune tolerance, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., November 2016
  • “Infections in the Immunocompromised Host,” Pediatric Hematology and Oncology Fellow Core Lecture Series, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., March 2017
  • “Immune Manipulations in Transplantation” Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapies Conference, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA., April 2017
  • “Successful engraftment, immune reconstitution, and clinical evidence of immune tolerance following cord blood and intestinal transplant for immunodeficiency and intestinal failure,” poster presentation, Pediatric Immune Deficiency Treatment Consortium Scientific Workshop, Bethesda, MD, May 2017
  • “Successful engraftment, immune reconstitution, and clinical evidence of immune tolerance following cord blood and intestinal transplant for immunodeficiency and intestinal failure,” oral presentation, Pediatric Immune Deficiency Treatment Consortium Educational Workshop, Bethesda, MD, May 2017
  • “Successful engraftment, immune reconstitution, and proper immune tolerance following cord blood and intestinal transplant for immunodeficiency and intestinal failure,” poster presentation, XV International Congress of the Intestinal Rehabilitation and Transplant Association, New York, NY, June 2017

Professional Affiliations/Society Memberships

  • American Society of Bone Marrow Transplantation
  • American Society of Hematology
  • American Society of Pediatric Hematology/Oncology
  • The Transplantation Society
  • Primary Immune Deficiency Treatment Consortium
  • Children’s Oncology Group

Education & Training

  • MD: Creighton University School of Medicine Omaha, NE
  • Residency: Stanford University Medical Center Stanford, CA
  • Fellowship: University of Minnesota Minneapolis, MN
  • Fellowship: St Jude Children's Research Hospital Memphis, TN

Research Interests

Haploidentical Viral Specific T-Lymphocytes to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV after Hematopoietic Cell Transplantation (HCT) or Solid Organ Transplantation (SOT)
Barnum focused on improving available therapy for patients with serious and often life-threatening viral infections after BMT. Available antivirals are quite toxic and often ineffective. She continued toward an institutional investigator-initiated protocol of T-cell immunotherapy for adenovirus, cytomegalovirus, and Epstein Barr virus.

Outcomes of Human Adenovirus (HAdV) Infection and Disease in Pediatric Allogeneic Stem Cell Transplant Recipients: A Prospective Multicenter Observational Cohort
Barnum was a coinvestigator and the BMT lead on this NIAID funded prospective multicenter trial designed to study risk factors for severe adenoviral infections in stem cell transplant recipients. This protocol opened at CHP in July 2017 and four patients were enrolled out of a projected 86 allogeneic transplant patients in the next 5 years.

Bilateral Orthotopic Lung Transplant in Tandem with CD3+ and CD19+ Cell-Depleted Bone Marrow Transplant from Partially HLA-Matched Cadaveric Donors
Barnum was a coinvestigator for the Tandem Solid Organ Transplant and T-Cell-Depleted Bone Marrow Transplant protocol. This new treatment modality was developed to transplant lungs followed by bone marrow, both procured from a partially HLA-matched cadaveric donor. The therapy addresses the unmet need to offer meaningful and high quality of life for those unfortunate children and young adults who have significant respiratory insufficiency and severe immune deficiency. Barnum was one of two physicians fully trained to procure vertebral bodies from cadaveric donors and has performed this procedure on two occasions. She has trained other faculty in this procedure and wrote an SOP for use in the operating room.

Naïve T-Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Barnum served as principal investigator on this CIBMTR study which is a multi-center, phase II randomized controlled trial comparing outcomes in pediatric patients receiving allogeneic hematopoietic cell transplantation using either naïve T cell-depleted peripheral blood stem cells or T cell-replete bone marrow. This trial has progressed to the initial feasibility phase, the randomized controlled trial will follow.

Use of Miltenyi Biotec’s CliniMACSâ CD34 Reagent System as a Humanitarian Use Device for Isolation of Hematopoietic Stem Cells or T-cell Depletion in Multiple Settings
Barnum wrote this protocol to study novel graft manipulation to decrease the risk of GVHD. It was used successfully for a patient with Fanconi anemia and many comorbidities. It remains open for other patients at CHP.

Primary Immune Deficiency Treatment Consortium protocol 6901: A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with Severe Combined Immune Deficiency Disorders
Barnum served as principal investigator on this multicenter, prospective protocol.

Primary Immune Deficiency Treatment Consortium protocol 6903: Analysis of Patients Treated for Chronic Granulomatous Disease Since 1995
Barnum served as coinvestigator on this multicenter, prospective, retrospective, and cross-sectional protocol.

Primary Immune Deficiency Treatment Consortium protocol 6904: Analysis of Patients Treated for Wiskott Aldrich Syndrome Since 1990
Barnum served as coinvestigator on this multicenter, prospective, retrospective, and cross-sectional protocol.

Division